| Document |
Document Title |
|
WO/2012/162334 |
Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: wherein R1, R2, R3, R4, R5, and R6 are independently hydrogen, C1-C6 alkyl or C1-C6 cycloalkyl; Y and Z are independently a C6-C10- aryl...
|
|
WO/2012/162635 |
Compounds that modulate GluR5 activity and methods of using the same are disclosed.
|
|
WO/2012/161622 |
The invention relates to the field of medicinal chemistry, pharmacology and medicine and contains a description of pharmaceutical compositions and combination drugs based on secretion stimulators and protectors of incretin hormones for t...
|
|
WO/2012/162124 |
Provided are methods of isolating a novel cell population of midbrain dopaminergic neuronal progenitor cells derived from stem cells using a novel combination markers. The cell population may be used for cell therapies for the treatment ...
|
|
WO/2012/161358 |
The present invention relates to a pharmaceutical composition for preventing or treating attention deficit hyperactivity disorder (ADHD), and more specifically, to a pharmaceutical composition for preventing or treating ADHD, containing ...
|
|
WO/2012/160713 |
The present invention aims to provide antidementia agents which are free from the problem of side effects and are excellent in safety. The present invention also aims to provide agents for improving learning and memory which are useful f...
|
|
WO/2012/161173 |
The present invention provides a substituted amide compound effective as a therapeutic agent for hypertension and such. The present invention provides a compound and such represented by general formula (I). (In the formula, R1 represents...
|
|
WO/2012/159456 |
A compound having the structure of formula I for use in preparing a CDC42 inhibitor. Morphological analysis of filopodia, a western blot of CDC42 phosphorylation, and experiments on cell wound healing and on growth cone formation all dem...
|
|
WO/2012/160358 |
The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydroc...
|
|
WO/2012/160333 |
Described are recombinant yeast comprising a nucleic acid sequence encoding human H-ferritin under the control of the yeast constitutive TDH3 transcriptional promoter, recombinant yeast comprising a nucleic acid sequence encoding human H...
|
|
WO/2012/161938 |
Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.
|
|
WO/2012/160130 |
The present invention relates to a method for treating spinal muscular atrophy and other related neuromuscular disorders in a subject in need thereof, said method comprising administering a therapeutically effective amount of an ERK inhi...
|
|
WO/2012/161519 |
The present invention relates to an adult stem cell line introduced with an HGF gene and a neurogenic transcription factor gene of a bHLH family, a preparation method of the adult stem cell line, a composition for the prevention or treat...
|
|
WO/2012/161301 |
A P2X4 receptor antagonist such as paroxetine and a diazepinedione derivative represented by general formula (IX) is used as a prophylactic or therapeutic agent for neuropathic pain associated with Guillain-Barre syndrome. (In the formul...
|
|
WO/2012/160333 |
Described are recombinant yeast comprising a nucleic acid sequence encoding human H-ferritin under the control of the yeast constitutive TDH3 transcriptional promoter, recombinant yeast comprising a nucleic acid sequence encoding human H...
|
|
WO/2012/160187 |
The present invention relates to amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the t...
|
|
WO/2012/160337 |
Compounds which interact with HlsTONES Compounds of Formula I : • 4"'-Sulfo-Fucose [alpha]1-3 (4"-sulfo)-Fucose [alpha]1-3 (4'-Sulfo-Fu- cose [alpha]1-4-Glucuronic acid [beta]1-0-Methyl or • 4" "-Sulfo-Fucose [alpha]1-3 (4"-sulfo)-Fu...
|
|
WO/2012/162330 |
Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: formula (I), wherein X is selected from the group of CH2, O, and NR2; m = 0 or 1; R1 at each instance is selected from the group of halo...
|
|
WO/2012/162339 |
The present invention relates to the use of teriflunomide for reducing occurrence of relapses requiring healthcare resources in patients having multiple sclerosis.
|
|
WO/2012/161527 |
The present invention relates to a pharmaceutical composition and to a food composition for preventing or treating neurodegenerative diseases, containing sandal tree extracts or fractions thereof as active ingredients, and to a method fo...
|
|
WO/2012/162254 |
The present invention provides compounds having a structure according to Formula I: (I) or a salt or solvate thereof, wherein R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the ...
|
|
WO/2012/156497 |
The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat type-2 diabetes-associated pain and related symptoms.
|
|
WO/2012/156931 |
The invention relates to hypophosphorous acid derivatives of formula (I) wherein - X is H or OH, - R represents one or several radicals R1-R5, identical or different, two of R1-R5 optionally occupying the same position on the phenyl grou...
|
|
WO/2012/156979 |
The invention disclosed relates to a water-soluble composition having enhanced bioavailability useful for the treatment of depression which comprises a synergistic combination of curcumin, at least an antioxidant, a hydrophilic carrier a...
|
|
WO/2012/158624 |
The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a c...
|
|
WO/2012/156308 |
The invention provides novel potent inhibitors of the ternary protein complex of nNOS, PSD-95, and the NMDA receptor and pharmaceutical compositions comprising the inhibitors for prophylaxis and/or treatment of excitotoxic-related diseas...
|
|
WO/2012/156317 |
The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥ 0.5 mg naloxone HCl dissolved in an ap...
|
|
WO/2012/159092 |
Nutraceutical formulations that improve cognitive function in adults diagnosed with neurodegenerative disease are provided, which comprise a combination of fisetin and DHA.
|
|
WO/2012/156666 |
The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of bindin...
|
|
WO/2012/156676 |
A monoclinic crystalline form of asenapine maleate is described, which is characterized in that it is not micronised and has a particle size distribution characterized by a d90 of 40 μm or less. A process for the preparation of a monocl...
|
|
WO/2012/156317 |
The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥ 0.5 mg naloxone HCl dissolved in an ap...
|
|
WO/2012/158892 |
|
|
WO/2012/156384 |
The present invention relates to novel crystalline salts of Asenapine and to methods of their preparation. In particular, the invention relates to crystalline Asenapine salts of tartaric acid or succinic acid, wherein the salts are e.g. ...
|
|
WO/2012/156309 |
The invention relates to antibodies against HER3 and their use in the treatment of cancer.
|
|
WO/2012/156731 |
The present invention relates to compositions including honey and L-alanyl-L- glutamine, pharmaceutical compositions thereof and a combined product comprising honey and L - alanyl - L - glutamine for a simultaneous, separate or sequentia...
|
|
WO/2012/157746 |
The present invention provides a screening method for a preventive or therapeutic agent for an autoimmune disease, comprising evaluating agonist activity or antagonist activity of a test compound on a lysophosphatidylserine receptor usin...
|
|
WO/2012/158492 |
Provided herein are methods of treating certain CNS disorders. Also provided herein are the biomarkers for monitoring or predicting the efficacy of a treatment for a CNS disorder by lurasidone, or a pharmaceutically acceptable salt, solv...
|
|
WO/2012/156383 |
The invention relates to novel crystalline salts of Asenapine (I) with organic di-acids and tri-acids and to methods of their preparation. Furthermore the invention relates to the use of the novel salts in pharmaceutical compositions and...
|
|
WO/2012/157612 |
The purpose of the present invention is to provide a cell differentiation inducer that is an easily chemically synthesizable low-molecular compound and capable of efficiently inducing the differentiation of undifferentiated cells into ne...
|
|
WO/2012/156225 |
The present invention refers to the use of anethole trithione, alone or in combination with other proper active principles, in the prevention and/or treatment of hyper-homocysteinemia and the consequent reduction of the risk of incidence...
|
|
WO/2012/158117 |
This invention generally relates to a combination therapy comprising the use of a substituted benzoimidazole compound and a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen, and, in particular, to the use of methyl 2-((2-(2,6...
|
|
WO/2012/158413 |
Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and Ring C are as defined herein, and wherein the Y-B moiety and the NH-C(...
|
|
WO/2012/155834 |
The present invention provides a preparation method for N-methyl-N-ethyl-carbamic acid 3-[(S)-1(dimethylamino)ethyl] phenyl ester (as represented by the compound in formula X). The present invention also provides the following intermedia...
|
|
WO/2012/158399 |
Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring G1, R1, and R2 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such ...
|
|
WO/2012/156968 |
Disclosed is the use of mesenchymal stem cells (MSCs) and in particular MSCs pretreated with pituitary adenylate cyclase-activating polypeptide (PACAP) or analogs and fragments of PACAP, for treatment of neurodegenerative and psychiatric...
|
|
WO/2012/156284 |
The present invention provides compounds of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds ...
|
|
WO/2012/157479 |
[Problem] The purpose of the present invention is to elucidate the biological function of CTRP6 and to put CTRP6 into practice. [Solution] A pharmaceutical composition for preventing or treating autoimmune diseases, which comprises CTRP6...
|
|
WO/2012/156968 |
Disclosed is the use of mesenchymal stem cells (MSCs) and in particular MSCs pretreated with pituitary adenylate cyclase-activating polypeptide (PACAP) or analogs and fragments of PACAP, for treatment of neurodegenerative and psychiatric...
|
|
WO/2012/156382 |
The invention relates to novel crystalline HCl salts of Asenapine and to methods of their preparation. Furthermore the invention relates to the use of the novel salts in pharmaceutical compositions and the use of the novel salts in the t...
|
|
WO/2012/159052 |
Embodiments of the invention are directed to compositions comprising a peptide sequence, or a nucleic acid encoding the same, wherein the peptide sequence includes a receptor-binding region of apolipoprotein E (apoE), or a sequence varia...
|
